Simplex Trading
CRVS icon

Simplex Trading’s Corvus Pharmaceuticals CRVS Stock Holding History

Simplex Trading’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$530K Sell
35,500
-33,500
-49% -$465K ﹤0.01% 3527
2026
Q1 		$1.01M Buy
69,000
+5,900
+9% +$94.2K ﹤0.01% 2490
2025
Q4 		$486K Buy
63,100
+16,100
+34% +$127K ﹤0.01% 3330
2025
Q3 		$346K Buy
47,000
+19,700
+72% +$101K ﹤0.01% 4282
2025
Q2 		$109K Sell
27,300
-12,100
-31% -$44K ﹤0.01% 5148
2025
Q1 		$125K Sell
39,400
-12,600
-24% -$59.3K ﹤0.01% 4824
2024
Q4 		$278K Buy
52,000
+15,700
+43% +$117K ﹤0.01% 4149
2024
Q3 		$191K Buy
36,300
+24,400
+205% +$87.6K ﹤0.01% 4559
2024
Q2 		$21K Buy
11,900
+3,500
+42% +$6.52K ﹤0.01% 6839
2024
Q1 		$14K Sell
8,400
-11,200
-57% -$23.4K ﹤0.01% 7366
2023
Q4 		$34K Buy
19,600
+8,600
+78% +$12.6K ﹤0.01% 6449
2023
Q3 		$16K Sell
11,000
-10,600
-49% -$22.4K ﹤0.01% 6803
2023
Q2 		$49K Buy
+21,600
New +$44.9K ﹤0.01% 5868
2023
Q1 		– Sell
-11,000
Closed -$9K – 9170
2022
Q4 		$9K Buy
11,000
+700
+7% +$619 ﹤0.01% 7610
2022
Q3 		$8K Buy
+10,300
New +$9.83K ﹤0.01% 8389
2022
Q2 		– Sell
-3,700
Closed -$6K – 10101
2022
Q1 		$6K Sell
3,700
-33,700
-90% -$61.7K ﹤0.01% 9268
2021
Q4 		$90K Buy
37,400
+31,300
+513% +$121K ﹤0.01% 6425
2021
Q3 		$16K Hold
6,100
– – ﹤0.01% 8604
2021
Q2 		$16K Buy
6,100
+6,083
+35,782% +$16.7K ﹤0.01% 8760
2021
Q1 		$5K Sell
17
-369
-96% -$1.33K ﹤0.01% 8190
2020
Q4 		$137K Buy
386
+362
+1,508% +$1.46K ﹤0.01% 5091
2020
Q3 		$9K Buy
+24
New +$96 ﹤0.01% 6833
2020
Q1 		– Sell
-30
Closed -$16K – 7682
2019
Q4 		$16K Buy
+30
New +$105 ﹤0.01% 6097

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Simplex Trading's CRVS Position: Q2 2026 in Review

Simplex Trading increased its Corvus Pharmaceuticals (CRVS) stake by 166% in Q2 2026, buying an estimated $800K and bringing the position to 92,343 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2416.

Simplex Trading first reported a position in CRVS in Q1 2020 and has held it in 19 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Simplex Trading held 92,343 shares of Corvus Pharmaceuticals worth $1.38M as of Q2 2026.
  • Simplex Trading bought 57,620 Corvus Pharmaceuticals shares in Q2 2026, an estimated $800K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #2416 holding.
  • Simplex Trading first reported a position in Corvus Pharmaceuticals in Q1 2020 and has held it in 19 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.